JYPC(SZ:002198)2017-04-26 16:00Financial Performance - The company's operating revenue for Q1 2017 was ¥78,461,064.68, representing a 6.89% increase compared to ¥73,401,318.83 in the same period last year[8] - The net profit attributable to shareholders for Q1 2017 was ¥7,835,931.73, a 1.64% increase from ¥7,709,611.51 in the previous year[8] - The net profit attributable to shareholders for the first half of 2017 decreased by 5.91% to a range of 1,500 to 1,594 million CNY[20] - The net profit for the first half of 2016 was 1,594.25 million CNY[20] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥15,249,516.29, a decline of 98.20% compared to -¥7,693,968.13 in the same period last year[8] - Cash received from operating activities increased by ¥4,750,800, an increase of 884.40%, mainly due to increased market deposits received by Jinsan Pharmaceutical[17] - Total assets at the end of the reporting period were ¥1,086,378,951.16, down 1.17% from ¥1,099,254,401.78 at the end of the previous year[8] Investment and Income - Investment income decreased by ¥703,400, a decline of 366.89%, primarily due to a decrease in net profit from the associated enterprise Huqingyuan Bio[16] - Other receivables increased by ¥39,806,600, a 185.36% rise, mainly due to increased petty cash at the office of Jinsan Pharmaceutical[15] Expectations and Commitments - The company expects a positive net profit attributable to shareholders for the first half of 2017, without a turnaround from losses[19] - The company did not report any overdue commitments from actual controllers, shareholders, or related parties during the reporting period[18] Performance Decline Factors - The decline in performance is attributed to increased market investment and promotional efforts, leading to higher sales expenses[20] - The weighted average return on net assets was 0.79%, a decrease of 0.04% from 0.83% in the previous year[8]